1. Home
  2. LDI vs BWAY Comparison

LDI vs BWAY Comparison

Compare LDI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo loanDepot Inc.

LDI

loanDepot Inc.

HOLD

Current Price

$0.98

Market Cap

607.4M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$15.23

Market Cap

578.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LDI
BWAY
Founded
2010
2003
Country
United States
Israel
Employees
N/A
129
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
607.4M
578.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LDI
BWAY
Price
$0.98
$15.23
Analyst Decision
Sell
Strong Buy
Analyst Count
3
2
Target Price
$3.00
$13.25
AVG Volume (30 Days)
1.9M
122.8K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.58
$309.69
Revenue Next Year
$13.99
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$0.93
$11.45
52 Week High
$5.05
$26.63

Technical Indicators

Market Signals
Indicator
LDI
BWAY
Relative Strength Index (RSI) 35.70 47.11
Support Level $0.93 $14.13
Resistance Level $1.32 $16.73
Average True Range (ATR) 0.07 0.91
MACD -0.00 -0.10
Stochastic Oscillator 21.40 25.08

Price Performance

Historical Comparison
LDI
BWAY

About LDI loanDepot Inc.

loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: